Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase ...

The FDA’s Oncologic Drugs Advisory Committee voted against an application for Columvi (glofitamab) plus GemOx for ...

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients – Updated data from the pivotal Phase III STARGLO study ...

Columvi combo for relapsed diffuse large B-cell lymphoma faces approval hurdle. Discover implications for U.S. Read more here ...

Swiss pharma major Roche (ROG: SIX) has reported updated results from its Phase III STARGLO trial, showing that a ...

What's more, both FDA Commissioner Martin Makary, M.D., and longtime FDA oncology chief Richard Pazdur, M.D., have a new ...

After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin ...

The FDA Oncologic Drug Advisory Committee meetings on Tuesday and Wednesday discussed therapies across lymphoma, multiple myeloma, bladder cancer, and prostate cancer.

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

Basel: Roche has announced that a US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussed ...

A panel of experts convened by the US regulator has given a cautious nod to Johnson & Johnson’s (Nasdaq: JNJ) Darzalex Faspro ...